Precision medicine in genetic epilepsies: break of dawn?

References

• Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369:1016–1026.
   PubMed Web of Science ®Google Scholar
• Thomas P, Valton L, Genton P. Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy. Brain. 2006;129:1281–1292.
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314–319.
   PubMed Web of Science ®Google Scholar
• Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12:157–165.
   PubMed Web of Science ®Google Scholar
• Lennox WG. The heredity of epilepsy as told by relatives and twins. J Am Med Assoc. 1951;146:529–536.
   PubMed Web of Science ®Google Scholar
• Vadlamudi L, Andermann E, Lombroso CT, et al. Epilepsy in twins: insights from unique historical data of William Lennox. Neurology. 2004;62:1127–1133.
   PubMed Web of Science ®Google Scholar
• Berkovic SF, Howell RA, Hay DA, et al. Epilepsies in twins: genetics of the major epilepsy syndromes. Ann Neurol. 1998;43:435–445.
   PubMed Web of Science ®Google Scholar
• Kjeldsen MJ, Corey LA, Christensen K, et al. Epileptic seizures and syndromes in twins: the importance of genetic factors. Epilepsy Res. 2003;55:137–146.
   PubMed Web of Science ®Google Scholar
• International League Against Epilepsy. Genetic determinants of common epilepsies: a meta-analysis of genome-wide association studies. Lancet Neurol. 2014;13:893–903.
   PubMed Web of Science ®Google Scholar
• Steffens M, Leu C, Ruppert AK, et al. Genome-wide association analysis of genetic generalized epilepsies implicates susceptibility loci at 1q43, 2p16.1, 2q22.3 and 17q21.32. Hum Mol Genet. 2012;21:5359–5372.
   PubMed Web of Science ®Google Scholar
• Thomas RH, Berkovic SF. The hidden genetics of epilepsy-a clinically important new paradigm. Nat Rev Neurol. 2014;10:283–292.
   PubMed Web of Science ®Google Scholar
• Epilepsy Phenome/Genome Project, Epi4K. De novo mutations in epileptic encephalopathies. Nature. 2013;501:217–221.
   PubMed Web of Science ®Google Scholar
• EuroEPINOMICS-RES Consortium, Epilepsy Phenome/Genome Project, Epi4K Consortium. De novo mutations in synaptic transmission genes including DNM1 cause epileptic encephalopathies. Am J Hum Genet. 2014;95:360–370.
   PubMed Web of Science ®Google Scholar
• Chung W, Hung S, Hong H, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428:486.
   PubMed Web of Science ®Google Scholar
• Claes L, Del-Favero J, Ceulemans B, et al. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet. 2001;68:1327–1332.
   PubMed Web of Science ®Google Scholar
• Marini C, Mei D, Temudo T, et al. Idiopathic epilepsies with seizures precipitated by fever and SCN1A abnormalities. Epilepsia. 2007;48:1678–1685.
   PubMed Web of Science ®Google Scholar
• Scheffer IE, Berkovic SF. Generalized epilepsy with febrile seizures plus. A genetic disorder with heterogeneous clin ical phenotypes. Brain. 1997;120:479–490.
   PubMed Web of Science ®Google Scholar
• Harkin LA, McMahon JM, Iona X, et al. The spectrum of SCN1A-related infantile epileptic encephalopathies. Brain. 2007;130:843–852.
   PubMed Web of Science ®Google Scholar
• Ogiwara I, Miyamoto H, Morita N, et al. Nav1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. J Neurosci. 2007;27:5903–5914.
   PubMed Web of Science ®Google Scholar
• Martin MS, Dutt K, Papale LA, et al. Altered function of the SCN1A voltage-gated sodium channel leads to gamma-aminobutyric acid-ergic (GABAergic) interneuron abnormalities. J Biol Chem. 2010;285:9823–9834.
   PubMed Web of Science ®Google Scholar
• Yu FH, Mantegazza M, Westenbroek RE, et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci. 2006;9:1142–1149.
   PubMed Web of Science ®Google Scholar
• Zuberi SM, Brunklaus A, Birch R, et al. Genotype-phenotype associations in SCN1A-related epilepsies. Neurology. 2011;76:594–600.
   PubMed Web of Science ®Google Scholar
• Guerrini R, Dravet C, Genton P, et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia. 1998;39:508–512.
   PubMed Web of Science ®Google Scholar
• Brunklaus A, Ellis R, Reavey E, et al. Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. Brain. 2012;135:2329–2336.
   PubMed Web of Science ®Google Scholar
• Dalic L, Mullen SA, Roulet Perez E, et al. Lamotrigine can be beneficial in patients with Dravet syndrome. Dev Med Child Neurol. 2015;57:200–202.
   PubMed Web of Science ®Google Scholar
• Tang B, Dutt K, Papale L, et al. A BAC transgenic mouse model reveals neuron subtype-specific effects of a generalized epilepsy with febrile seizures plus (GEFS+) mutation. Neurobiol Dis. 2009;35:91–102.
   PubMed Web of Science ®Google Scholar
• Wilmshurst JM, Gaillard WD, Vinayan KP, et al. Summary of recommendations for the management of infantile seizures: task force report for the ILAE commission of pediatrics. Epilepsia. 2015;56:1185–1197.
   PubMed Web of Science ®Google Scholar
• Chiron C. Stiripentol. Neurotherapeutics. 2007;4:123–125.
   PubMed Web of Science ®Google Scholar
• Sada N, Lee S, Katsu T, et al. Epilepsy treatment. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science. 2015;347:1362–1367.
   PubMed Web of Science ®Google Scholar
• McCann UD, Seiden LS, Rubin LJ, et al. Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence. JAMA. 1997;278:666–672.
   PubMed Web of Science ®Google Scholar
• Dahl CF, Allen MR, Urie PM, et al. Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals. BMC Med. 2008;6:34.
   PubMed Web of Science ®Google Scholar
• Fuller RW, Snoddy HD, Robertson DW. Mechanisms of effects of d-fenfluramine on brain serotonin metabolism in rats: uptake inhibition versus release. Pharmacol Biochem Behav. 1988;30:715–721.
   PubMed Web of Science ®Google Scholar
• Ceulemans B, Boel M, Leyssens K, et al. Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia. 2012;53:1131–1139.
   PubMed Web of Science ®Google Scholar
• Ceulemans B, Schoonjans A, Marchau F, et al. Five-year extended follow-up status of 10 patients with Dravet syndrome treated with fenfluramine. Epilepsia. 2016;57:e129–34.
   PubMed Web of Science ®Google Scholar
• Seidner G, Alvarez MG, Yeh JI, et al. GLUT-1 deficiency syndrome caused by haploinsufficiency of the blood-brain barrier hexose carrier. Nat Genet. 1998;18:188–191.
   PubMed Web of Science ®Google Scholar
• De Vivo DC, Trifiletti RR, Jacobson RI, et al. Defective glucose transport across the blood-brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay. N Engl J Med. 1991;325:703–709.
   PubMed Web of Science ®Google Scholar
• Weber YG, Storch A, Wuttke TV, et al. GLUT1 mutations are a cause of paroxysmal exertion-induced dyskinesias and induce hemolytic anemia by a cation leak. J Clin Investig. 2008;118:2157–2168.
   PubMed Web of Science ®Google Scholar
• Suls A, Dedeken P, Goffin K, et al. Paroxysmal exercise-induced dyskinesia and epilepsy is due to mutations in SLC2A1, encoding the glucose transporter GLUT1. Brain. 2008;131:1831–1844.
   PubMed Web of Science ®Google Scholar
• Suls A, Mullen SA, Weber YG, et al. Early-onset absence epilepsy caused by mutations in the glucose transporter GLUT1. Ann Neurol. 2009;66:415–419.
   PubMed Web of Science ®Google Scholar
• Arsov T, Mullen SA, Damiano JA, et al. Early onset absence epilepsy: 1 in 10 cases is caused by GLUT1 deficiency. Epilepsia. 2012;53:e204–7.
   PubMed Web of Science ®Google Scholar
• Mullen SA, Marini C, Suls A, et al. Glucose transporter 1 deficiency as a treatable cause of myoclonic astatic epilepsy. Archives of Neurology. 2011;68:1152–1155.
   PubMedGoogle Scholar
• Mullen SA, Suls A, de Jonghe P, et al. Absence epilepsies with widely variable onset are a key feature of familial GLUT1 deficiency. Neurology. 2010;75:432–440.
   PubMed Web of Science ®Google Scholar
• Striano P, Weber YG, Toliat MR, et al. GLUT1 mutations are a rare cause of familial idiopathic generalized epilepsy. Neurology. 2012;78:557–562.
   PubMed Web of Science ®Google Scholar
• Arsov T, Mullen SA, Rogers S, et al. Glucose transporter 1 deficiency in the idiopathic generalized epilepsies. Ann Neurol. 2012;72:807–815.
   PubMed Web of Science ®Google Scholar
• Klepper J, Diefenbach S, Kohlschütter A, et al. Effects of the ketogenic diet in the glucose transporter 1 deficiency syndrome. Prostaglandins Leukot Essent Fatty Acids. 2004;70:321–327.
   PubMed Web of Science ®Google Scholar
• Kass HR, Winesett SP, Bessone SK, et al. Use of dietary therapies amongst patients with GLUT1 deficiency syndrome. Seizure. 2016;35:83–87.
   PubMed Web of Science ®Google Scholar
• Gumus H, Bayram AK, Kardas F, et al. The effects of ketogenic diet on seizures, cognitive functions, and other neurological disorders in classical phenotype of glucose transporter 1 deficiency syndrome. Neuropediatrics. 2015;46:313–320.
   PubMed Web of Science ®Google Scholar
• Fujii T, Ito Y, Takahashi S, et al. Outcome of ketogenic diets in GLUT1 deficiency syndrome in Japan: a nationwide survey. Brain Dev. 2016. DOI:10.1016/j.braindev.2016.01.002
   Web of Science ®Google Scholar
• Amalou S, Gras D, Ilea A, et al. Use of modified Atkins diet in glucose transporter type 1 deficiency syndrome. Dev Med Child Neurol. 2016 cited 2016 Jun 8. DOI:10.1111/dmcn.13167
   PubMed Web of Science ®Google Scholar
• Singh NA, Charlier C, Stauffer D, et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet. 1998;18:25–29.
   PubMed Web of Science ®Google Scholar
• Miles DK, Holmes GL. Benign neonatal seizures. J Clin Neurophysiol. 1990;7:369–379.
   PubMed Web of Science ®Google Scholar
• Grinton BE, Heron SE, Pelekanos JT, et al. Familial neonatal seizures in 36 families: clinical and genetic features correlate with outcome. Epilepsia. 2015;56:1071–1080.
   PubMed Web of Science ®Google Scholar
• Weckhuysen S, Mandelstam S, Suls A, et al. KCNQ2 encephalopathy: emerging phenotype of a neonatal epileptic encephalopathy. Ann Neurol. 2012;71:15–25.
   PubMed Web of Science ®Google Scholar
• Weckhuysen S, Ivanovic V, Hendrickx R, et al. Extending the KCNQ2 encephalopathy spectrum: clinical and neuroimaging findings in 17 patients. Neurology. 2013;81:1697–1703.
   PubMed Web of Science ®Google Scholar
• Kato M, Yamagata T, Kubota M, et al. Clinical spectrum of early onset epileptic encephalopathies caused by KCNQ2 mutation. Epilepsia. 2013;54:1282–1287.
   PubMed Web of Science ®Google Scholar
• Orhan G, Bock M, Schepers D, et al. Dominant-negative effects of KCNQ2 mutations are associated with epileptic encephalopathy. Ann Neurol. 2014;75:382–394.
   PubMed Web of Science ®Google Scholar
• Miceli F, Soldovieri MV, Ambrosino P, et al. Early-onset epileptic encephalopathy caused by gain-of-function mutations in the voltage sensor of Kv7.2 and Kv7.3 potassium channel subunits. J Neurosci. 2015;35:3782–3793.
   PubMed Web of Science ®Google Scholar
• Devaux J, Abidi A, Roubertie A, et al. A Kv7.2 mutation associated with early onset epileptic encephalopathy with suppression-burst enhances Kv7/M channel activity. Epilepsia. 2016;57:e87–93.
   Google Scholar
• Wang J, Li Y, Hui Z, et al. Functional analysis of potassium channels in Kv7.2 G271V mutant causing early onset familial epilepsy. Brain Res. 2015;1616:112–122.
   PubMed Web of Science ®Google Scholar
• Ihara Y, Tomonoh Y, Deshimaru M, et al. Retigabine, a Kv7.2/Kv7.3-channel opener, attenuates drug-induced seizures in knock-in mice harboring Kcnq2 mutations. PLoS One. 2016;11:e0150095.
   PubMed Web of Science ®Google Scholar
• Millichap JJ, Park KL, Tsuchida T, et al. KCNQ2 encephalopathy: features, mutational hot spots, and ezogabine treatment of 11 patients. Neurol Genet. 2016;2:e96.
   PubMed Web of Science ®Google Scholar
• Numis AL, Angriman M, Sullivan JE, et al. KCNQ2 encephalopathy: delineation of the electroclinical phenotype and treatment response. Neurology. 2014;82:368–370.
   PubMed Web of Science ®Google Scholar
• Pisano T, Numis AL, Heavin SB, et al. Early and effective treatment of KCNQ2 encephalopathy. Epilepsia. 2015;56:685–691.
   PubMed Web of Science ®Google Scholar
• Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372:657–668.
   PubMed Web of Science ®Google Scholar
• Saxena A, Sampson JR. Epilepsy in tuberous sclerosis: phenotypes, mechanisms, and Treatments. Semin Neurol. 2015;35:269–276.
   PubMed Web of Science ®Google Scholar
• Curatolo P, Moavero R, Roberto D, et al. Genotype/phenotype correlations in tuberous sclerosis complex. Semin Pediatr Neurol. 2015;22:259–273.
   PubMed Web of Science ®Google Scholar
• Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363:1801–1811.
   PubMed Web of Science ®Google Scholar
• Krueger DA, Wilfong AA, Holland-Bouley K, et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol. 2013;74:679–687.
   PubMed Web of Science ®Google Scholar
• Franz DN, Agricola K, Mays M, et al. Everolimus for subependymal giant cell astrocytoma: 5-year final analysis. Ann Neurol. 2015;78:929–938.
   PubMed Web of Science ®Google Scholar
• French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016 cited 2016 Sep 6. DOI:10.1016/S0140-6736(16)31419-2
   Web of Science ®Google Scholar
• Dibbens LM, de Vries B, Donatello S, et al. Mutations in DEPDC5 cause familial focal epilepsy with variable foci. Nat Genet. 2013;45:546–551.
   PubMed Web of Science ®Google Scholar
• Ishida S, Picard F, Rudolf G, et al. Mutations of DEPDC5 cause autosomal dominant focal epilepsies. Nat Genet. 2013;45:552–555.
   PubMed Web of Science ®Google Scholar
• Martin C, Meloche C, Rioux MF, et al. A recurrent mutation in DEPDC5 predisposes to focal epilepsies in the French-Canadian population. Clin Genet. 2014;86:570–574.
   PubMed Web of Science ®Google Scholar
• Scheffer IE, Phillips HA, O’Brien CE, et al. Familial partial epilepsy with variable foci: a new partial epilepsy syndrome with suggestion of linkage to chromosome 2. Ann Neurol. 1998;44:890–899.
   PubMed Web of Science ®Google Scholar
• Xiong L, Labuda M, Li DS, et al. Mapping of a gene determining familial partial epilepsy with variable foci to chromosome 22q11-q12. Am J Hum Genet. 1999;65:1698–1710.
   PubMed Web of Science ®Google Scholar
• Callenbach P, van den Maagdenberg AM, Hottenga JJ, et al. Familial partial epilepsy with variable foci in a Dutch family: clinical characteristics and confirmation of linkage to chromosome 22q. Epilepsia. 2003;44:1298–1305.
   PubMed Web of Science ®Google Scholar
• Berkovic SF, Serratosa JM, Phillips HA, et al. Familial partial epilepsy with variable foci: clinical features and linkage to chromosome 22q12. Epilepsia. 2004;45:1054–1060.
   PubMed Web of Science ®Google Scholar
• Morales-Corraliza J, Gómez-Garre P, Sanz R, et al. Familial partial epilepsy with variable foci: a new family with suggestion of linkage to chromosome 22q12. Epilepsia. 2010;51:1910–1914.
   PubMed Web of Science ®Google Scholar
• Klein KM, O’Brien TJ, Praveen K, et al. Familial focal epilepsy with variable foci mapped to chromosome 22q12: expansion of the phenotypic spectrum. Epilepsia. 2012;53:e151–5.
   PubMed Web of Science ®Google Scholar
• Picard F, Makrythanasis P, Navarro V, et al. DEPDC5 mutations in families presenting as autosomal dominant nocturnal frontal lobe epilepsy. Neurology. 2014;82:2101–2106.
   PubMed Web of Science ®Google Scholar
• Striano P, Serioli E, Santulli L, et al. DEPDC5 mutations are not a frequent cause of familial temporal lobe epilepsy. Epilepsia. 2015;56:e168–71.
   PubMed Web of Science ®Google Scholar
• Lal D, Reinthaler EM, Schubert J, et al. DEPDC5 mutations in genetic focal epilepsies of childhood. Ann Neurol. 2014;75:788–792.
   PubMed Web of Science ®Google Scholar
• Carvill GL, Crompton DE, Regan BM, et al. Epileptic spasms are a feature of DEPDC5 mTORopathy. Neurol Genet. 2015;1:e17.
   PubMedGoogle Scholar
• Bar-Peled L, Chantranupong L, Cherniack AD, et al. A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science. 2013;340:1100–1106.
   PubMed Web of Science ®Google Scholar
• Scheffer IE, Heron SE, Regan BM, et al. Mutations in mTOR regulator DEPDC5 cause focal epilepsy with brain malformations. Ann Neurol. 2014;75:782–787.
   PubMed Web of Science ®Google Scholar
• Baulac S, Ishida S, Marsan E, et al. Familial focal epilepsy with focal cortical dysplasia due to DEPDC5 mutations. Ann Neurol. 2015;77:675–683.
   PubMed Web of Science ®Google Scholar
• Scerri T, Riseley JR, Gillies G, et al. Familial cortical dysplasia type IIA caused by a germline mutation in DEPDC5. Ann Clin Transl Neurol. 2015;2:575–580.
   PubMed Web of Science ®Google Scholar
• Ricos MG, Hodgson BL, Pippucci T, et al. Mutations in the mammalian target of rapamycin pathway regulators NPRL2 and NPRL3 cause focal epilepsy. Ann Neurol. 2016;79:120–131.
   PubMed Web of Science ®Google Scholar
• Sim JC, Scerri T, Fanjul-Fernández M, et al. Familial cortical dysplasia caused by mutation in the mammalian target of rapamycin regulator NPRL3. Ann Neurol. 2016;79:132–137.
   PubMed Web of Science ®Google Scholar
• Weckhuysen S, Marsan E, Lambrecq V, et al. Involvement of GATOR complex genes in familial focal epilepsies and focal cortical dysplasia. Epilepsia. 2016;57:994–1003.
   PubMed Web of Science ®Google Scholar
• Korenke G, Eggert M, Thiele H, et al. Nocturnal frontal lobe epilepsy caused by a mutation in the GATOR1 complex gene NPRL3. Epilepsia. 2016;57:e60–3.
   PubMed Web of Science ®Google Scholar
• Liao Y, Anttonen AK, Liukkonen E, et al. SCN2A mutation associated with neonatal epilepsy, late-onset episodic ataxia, myoclonus, and pain. Neurology. 2010;75:1454–1458.
   PubMed Web of Science ®Google Scholar
• Heron SE, Crossland KM, Andermann E, et al. Sodium-channel defects in benign familial neonatal-infantile seizures. Lancet. 2002;360:851–852.
   PubMed Web of Science ®Google Scholar
• Howell KB, McMahon JM, Carvill GL, et al. SCN2A encephalopathy: a major cause of epilepsy of infancy with migrating focal seizures. Neurology. 2015;85:958–966.
   PubMed Web of Science ®Google Scholar
• Ogiwara I, Ito K, Sawaishi Y, et al. De novo mutations of voltage-gated sodium channel alphaII gene SCN2A in intractable epilepsies. Neurology. 2009;73:1046–1053.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Kato M, Osaka H, et al. Clinical spectrum of SCN2A mutations expanding to Ohtahara syndrome. Neurology. 2013;81:992–998.
   PubMed Web of Science ®Google Scholar
• Sanders SJ, Murtha MT, Gupta AR, et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature. 2012;485:237–241.
   PubMed Web of Science ®Google Scholar
• Trump N, McTague A, Brittain H, et al. Improving diagnosis and broadening the phenotypes in early-onset seizure and severe developmental delay disorders through gene panel analysis. J Med Genet. 2016;53:310–317.
   PubMed Web of Science ®Google Scholar
• Kamiya K, Kaneda M, Sugawara T, et al. A nonsense mutation of the sodium channel gene SCN2A in a patient with intractable epilepsy and mental decline. J Neurosci. 2004;24:2690–2698.
   PubMed Web of Science ®Google Scholar
• Baasch AL, Huning I, Gilissen C, et al. Exome sequencing identifies a de novo SCN2A mutation in a patient with intractable seizures, severe intellectual disability, optic atrophy, muscular hypotonia, and brain abnormalities. Epilepsia. 2014;55:e25–9.
   Google Scholar
• Meisler MH, O’Brien JE, Sharkey LM. Sodium channel gene family: epilepsy mutations, gene interactions and modifier effects. J Physiol. 2010;588:1841–1848.
   PubMed Web of Science ®Google Scholar
• Misra SN, Kahlig KM, George AL Jr. Impaired NaV1.2 function and reduced cell surface expression in benign familial neonatal-infantile seizures. Epilepsia. 2008;49:1535–1545.
   PubMed Web of Science ®Google Scholar
• Horvath GA, Demos M, Shyr C, et al. Secondary neurotransmitter deficiencies in epilepsy caused by voltage-gated sodium channelopathiesa potential treatment target? Mol Genet Metab. 2016;117:42–48.
   PubMed Web of Science ®Google Scholar
• Wagnon JL, Meisler MH. Recurrent and non-recurrent mutations of SCN8A in epileptic encephalopathy. Front Neurol. 2015;6:104.
   PubMed Web of Science ®Google Scholar
• Carvill GL, Heavin SB, Yendle SC, et al. Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. Nat Genet. 2013;45:825–830.
   PubMed Web of Science ®Google Scholar
• Larsen J, Carvill GL, Gardella E, et al. The phenotypic spectrum of SCN8A encephalopathy. Neurology. 2015;84:480–489.
   PubMed Web of Science ®Google Scholar
• Ohba C, Kato M, Takahashi S, et al. Early onset epileptic encephalopathy caused by de novo SCN8A mutations. Epilepsia. 2014;55:994–1000.
   PubMed Web of Science ®Google Scholar
• Trudeau MM, Dalton JC, Day JW, et al. Heterozygosity for a protein truncation mutation of sodium channel SCN8A in a patient with cerebellar atrophy, ataxia, and mental retardation. J Med Genet. 2006;43:527–530.
   PubMed Web of Science ®Google Scholar
• Veeramah KR, O’Brien JE, Meisler MH, et al. De novo pathogenic SCN8A mutation identified by whole-genome sequencing of a family quartet affected by infantile epileptic encephalopathy and SUDEP. Am J Hum Genet. 2012;90:502–510.
   PubMed Web of Science ®Google Scholar
• Kong W, Zhang Y, Gao Y, et al. SCN8A mutations in Chinese children with early onset epilepsy and intellectual disability. Epilepsia. 2015;56:431–438.
   PubMed Web of Science ®Google Scholar
• Wagnon JL, Korn MJ, Parent R, et al. Convulsive seizures and SUDEP in a mouse model of SCN8A epileptic encephalopathy. Hum Mol Genet. 2015;24:506–515.
   PubMed Web of Science ®Google Scholar
• Blanchard MG, Willemsen MH, Walker JB, et al. De novo gain-of-function and loss-of-function mutations of SCN8A in patients with intellectual disabilities and epilepsy. J Med Genet. 2015;52:330–337.
   PubMed Web of Science ®Google Scholar
• Boerma RS, Braun KP, van den Broek MP, et al. Remarkable phenytoin sensitivity in 4 children with SCN8A-related epilepsya molecular neuropharmacological approach. Neurotherapeutics. 2016;13:192–197.
   PubMed Web of Science ®Google Scholar
• Dyment DA, Tétreault M, Beaulieu CL, et al. Whole-exome sequencing broadens the phenotypic spectrum of rare pediatric epilepsy: a retrospective study. Clin Genet. 2015;88:34–40.
   PubMed Web of Science ®Google Scholar
• Mercimek-Mahmutoglu S, Patel J, Cordeiro D, et al. Diagnostic yield of genetic testing in epileptic encephalopathy in childhood. Epilepsia. 2015;56:707–716.
   PubMed Web of Science ®Google Scholar
• Vaher U, Nõukas M, Nikopensius T, et al. De novo SCN8A mutation identified by whole-exome sequencing in a boy with neonatal epileptic encephalopathy, multiple congenital anomalies, and movement disorders. J Child Neurol. 2014;29:NP202–6.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Yamamoto S, Okayama A, et al. Electroclinical features of epileptic encephalopathy caused by SCN8A mutation. Pediatr Int. 2015;57:758–762.
   PubMed Web of Science ®Google Scholar
• Anand G, Collett-White F, Orsini A, et al. Autosomal dominant SCN8A mutation with an unusually mild phenotype. Eur J Paediatr Neurol. 2016;20:761–765.
   PubMed Web of Science ®Google Scholar
• Singh R, Jayapal S, Goyal S, et al. Early-onset movement disorder and epileptic encephalopathy due to de novo dominant SCN8A mutation. Seizure. 2015;26:69–71.
   PubMed Web of Science ®Google Scholar
• de Kovel CGF, Meisler MH, Brilstra EH, et al. Characterization of a de novo SCN8A mutation in a patient with epileptic encephalopathy. Epilepsy Res. 2014;108:1511–1518.
   PubMed Web of Science ®Google Scholar
• Estacion M, O’Brien JE, Conravey A, et al. A novel de novo mutation of SCN8A (Nav1.6) with enhanced channel activation in a child with epileptic encephalopathy. Neurobiol Dis. 2014;69:117–123.
   PubMed Web of Science ®Google Scholar
• Barker BS, Ottolini M, Wagnon JL, et al. The SCN8A encephalopathy mutation p.Ile1327Val displays elevated sensitivity to the anticonvulsant phenytoin. Epilepsia. 2016. DOI:10.1111/epi.13461
   PubMed Web of Science ®Google Scholar
• Barcia G, Fleming MR, Deligniere A, et al. De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy. Nat Genet. 2012;44:1255–1259.
   PubMed Web of Science ®Google Scholar
• Bhattacharjee A, Gan L, Kaczmarek LK. Localization of the Slack potassium channel in the rat central nervous system. J Comp Neurol. 2002;454:241–254.
   PubMed Web of Science ®Google Scholar
• Yuan A, Santi CM, Wei A, et al. The sodium-activated potassium channel is encoded by a member of the Slo gene family. Neuron. 2003;37:765–773.
   PubMed Web of Science ®Google Scholar
• Heron SE, Smith KR, Bahlo M, et al. Missense mutations in the sodium-gated potassium channel gene KCNT1 cause severe autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet. 2012;44:1188–1190.
   PubMed Web of Science ®Google Scholar
• Vanderver A, Simons C, Schmidt JL, et al. Identification of a novel de novo p.Phe932Ile KCNT1 mutation in a patient with leukoencephalopathy and severe epilepsy. Pediatr Neurol. 2014;50:112–114.
   PubMed Web of Science ®Google Scholar
• McTague A, Appleton R, Avula S, et al. Migrating partial seizures of infancy: expansion of the electroclinical, radiological and pathological disease spectrum. Brain. 2013;136:1578–1591.
   PubMed Web of Science ®Google Scholar
• Coppola G, Plouin P, Chiron C, et al. Migrating partial seizures in infancy: a malignant disorder with developmental arrest. Epilepsia. 1995;36:1017–1024.
   PubMed Web of Science ®Google Scholar
• Moller RS, Heron SE, Larsen LH, et al. Mutations in KCNT1 cause a spectrum of focal epilepsies. Epilepsia. 2015;56:e114–20.
   PubMed Web of Science ®Google Scholar
• Ishii A, Shioda M, Okumura A, et al. A recurrent KCNT1 mutation in two sporadic cases with malignant migrating partial seizures in infancy. Gene. 2013;531:467–471.
   PubMed Web of Science ®Google Scholar
• Kim GE, Kaczmarek LK. Emerging role of the KCNT1 Slack channel in intellectual disability. Front Cell Neurosci. 2014;8:209.
   PubMed Web of Science ®Google Scholar
• Villa C, Combi R. Potassium channels and human epileptic phenotypes: an updated overview. Front Cell Neurosci. 2016;10:81.
   PubMed Web of Science ®Google Scholar
• Yang B, Gribkoff VK, Pan J, et al. Pharmacological activation and inhibition of Slack (Slo2.2) channels. Neuropharmacology. 2006;51:896–906.
   PubMed Web of Science ®Google Scholar
• Milligan CJ, Li M, Gazina EV, et al. KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine. Ann Neurol. 2014;75:581–590.
   PubMed Web of Science ®Google Scholar
• Bearden D, Strong A, Ehnot J, et al. Targeted treatment of migrating partial seizures of infancy with quinidine. Ann Neurol. 2014;76:457–461.
   PubMed Web of Science ®Google Scholar
• Mikati MA, Jiang Y, Carboni M, et al. Quinidine in the treatment of KCNT1-positive epilepsies. Ann Neurol. 2015;78:995–999.
   PubMed Web of Science ®Google Scholar
• Chong PF, Nakamura R, Saitsu H, et al. Ineffective quinidine therapy in early onset epileptic encephalopathy with KCNT1 mutation. Ann Neurol. 2016;79:502–503.
   PubMed Web of Science ®Google Scholar
• Rizzo F, Ambrosino P, Guacci A, et al. Characterization of two de novoKCNT1 mutations in children with malignant migrating partial seizures in infancy. Mol Cell Neurosci. 2016;72:54–63.
   PubMed Web of Science ®Google Scholar
• Brew HM, Gittelman JX, Silverstein RS, et al. Seizures and reduced life span in mice lacking the potassium channel subunit Kv1.2, but hypoexcitability and enlarged Kv1 currents in auditory neurons. J Neurophysiol. 2007;98:1501–1525.
   PubMed Web of Science ®Google Scholar
• Syrbe S, Hedrich UB, Riesch E, et al. De novo loss- or gain-of-function mutations in KCNA2 cause epileptic encephalopathy. Nat Genet. 2015;47:393–399.
   PubMed Web of Science ®Google Scholar
• Pena SDJ, Coimbra RLM. Ataxia and myoclonic epilepsy due to a heterozygous new mutation in KCNA2: proposal for a new channelopathy. Clin Genet. 2015;87:e1–3.
   Google Scholar
• Ramaswami M, Gautam M, Kamb A, et al. Human potassium channel genes: molecular cloning and functional expression. Mol Cell Neurosci. 1990;1:214–223.
   PubMedGoogle Scholar
• Glasgow NG, Siegler Retchless B, Johnson JW. Molecular bases of NMDA receptor subtype-dependent properties. J Physiol. 2015;593:83–95.
   PubMed Web of Science ®Google Scholar
• Endele S, Rosenberger G, Geider K, et al. Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes. Nat Genet. 2010;42:1021–1026.
   PubMed Web of Science ®Google Scholar
• Reutlinger C, Helbig I, Gawelczyk B, et al. Deletions in 16p13 including GRIN2A in patients with intellectual disability, various dysmorphic features, and seizure disorders of the rolandic region. Epilepsia. 2010;51:1870–1873.
   PubMed Web of Science ®Google Scholar
• Lesca G, Rudolf G, Labalme A, et al. Epileptic encephalopathies of the Landau-Kleffner and continuous spike and waves during slow-wave sleep types: genomic dissection makes the link with autism. Epilepsia. 2012;53:1526–1538.
   PubMed Web of Science ®Google Scholar
• Lemke JR, Lal D, Reinthaler EM, et al. Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic spikes. Nat Genet. 2013;45:1067–1072.
   PubMed Web of Science ®Google Scholar
• Carvill GL, Regan BM, Yendle SC, et al. GRIN2A mutations cause epilepsy-aphasia spectrum disorders. Nat Genet. 2013;45:1073–1076.
   PubMed Web of Science ®Google Scholar
• Lesca G, Rudolf G, Bruneau N, et al. GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. Nat Genet. 2013;45:1061–1066.
   PubMed Web of Science ®Google Scholar
• Lemke JR, Hendrickx R, Geider K, et al. GRIN2B mutations in West syndrome and intellectual disability with focal epilepsy. Ann Neurol. 2014;75:147–154.
   PubMed Web of Science ®Google Scholar
• Turner SJ, Mayes AK, Verhoeven A, et al. GRIN2A: an aptly named gene for speech dysfunction. Neurology. 2015;84:586–593.
   PubMed Web of Science ®Google Scholar
• Wirrell EC. Benign epilepsy of childhood with centrotemporal spikes. Epilepsia. 1998;39(Suppl 4):S32–41.
   Google Scholar
• Marwick K, Skehel P, Hardingham G, et al. Effect of a GRIN2A de novo mutation associated with epilepsy and intellectual disability on NMDA receptor currents and Mg(2+) block in cultured primary cortical neurons. Lancet. 2015;385(Suppl 1):S65.
   Google Scholar
• Yuan H, Hansen KB, Zhang J, et al. Functional analysis of a de novo GRIN2A missense mutation associated with early-onset epileptic encephalopathy. Nat Commun. 2014;5:3251.
   PubMed Web of Science ®Google Scholar
• Monyer H, Burnashev N, Laurie DJ, et al. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron. 1994;12:529–540.
   PubMed Web of Science ®Google Scholar
• Vicini S, Wang JF, Li JH, et al. Functional and pharmacological differences between recombinant N-methyl-D-aspartate receptors. J Neurophysiol. 1998;79:555–566.
   PubMed Web of Science ®Google Scholar
• Pierson TM, Yuan H, Marsh ED, et al. GRIN2A mutation and early-onset epileptic encephalopathy: personalized therapy with memantine. Ann Clin Transl Neurol. 2014;1:190–198.
   PubMed Web of Science ®Google Scholar
• de Sarro G, Ongini E, Bertorelli R, et al. Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA/2 mice. Eur J Pharmacol. 1994;262:11–19.
   PubMed Web of Science ®Google Scholar
• Harty TP, Rogawski MA. Felbamate block of recombinant N-methyl-D-aspartate receptors: selectivity for the NR2B subunit. Epilepsy Res. 2000;39:47–55.
   PubMed Web of Science ®Google Scholar
• Pellock JM. Felbamate. Epilepsia. 1999;40(Suppl 5):S57–62.
   PubMed Web of Science ®Google Scholar
• Volkmann RA, Fanger CM, Anderson DR, et al. MPX-004 and MPX-007: new pharmacological tools to study the physiology of NMDA receptors containing the GluN2A subunit. PLoS One. 2016;11:e0148129.
   PubMed Web of Science ®Google Scholar